America has a medical bureaucracy problem that is disincentivizing the next generation of prevention technologies for chronic disease. Three in four adults have a chronic condition , and yet less than 3% of our $5 trillion health care economy is focused on prevention. We may lead the world in biomedical discovery, but we struggle to incorporate new screening tests and diagnostics into routine care.

Our regulatory system is part of the problem. When the FDA approves a drug, it enters the market almost immediately: Physicians prescribe it and insurers decide how to cover it. Early detection technologies face a second quasi-regulatory hurdle: a little-known but influential advisory group called the U.S. Preventive Services Task Force, or USPSTF.

FDA authorization does not create

See Full Page